Skip Navigation


Annals of Oncology Advance Access originally published online on May 21, 2007
Annals of Oncology 2007 18(9):1477-1483; doi:10.1093/annonc/mdm209
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/9/1477    most recent
mdm209v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Conforti, R
Right arrow Articles by Andre, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conforti, R
Right arrow Articles by Andre, F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast cancer

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials

R Conforti1,{dagger}, T Boulet2,{dagger}, G Tomasic3,{dagger}, E Taranchon3, R Arriagada4, M Spielmann5, M Ducourtieux2, JC Soria5, T Tursz5, S Delaloge1,5, S Michiels2 and F Andre1,5,*

1 Translational research unit, Unite Propre de Recherche de l'enseignement supérieur, équipe d'accueil 03535
2 Biostatistics, and Epidemiology Unit
3 Department of Pathology
4 Department of Radiation Oncology
5 Department of Medicine, Institut Gustave Roussy, Villejuif, France

* Correspondence to: Dr F. Andre, Breast Cancer Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France. Tel: +33-1-42114371; Fax: +33-1-42115274; E-mail. fandre{at}igr.fr

Background: The purpose of this study was to determine the predictive value of breast cancer molecular subclassification regarding the benefit of adjuvant anthracycline-based chemotherapy.

Patients and methods: Tumor samples from 823 patients included in two randomized trials that compared an anthracycline-based chemotherapy with no treatment were used to construct a tissue array. Estrogen receptor (ER), Her2, epidermal growth factor receptor, cytokeratine 5/6 expressions were determined by immunohistochemistry (IHC). The potential predictive factors of treatment effect on disease-free survival (DFS) were assessed by interaction tests and multivariate analysis.

Results: Sixty-four (8%), 98 (12%), 109 (14%) and 527 (66%) patients presented a Her2+/ER–, basal-like, Her2–/ER–/nonbasal and luminal-like breast cancer. ER expression, when assessed by IHC, was an independent predictive factor for the benefit of chemotherapy on DFS (test for interaction, P = 0.0015). The molecular subclassification significantly predicted the efficacy of chemotherapy (test for interaction, P = 0.01), but had no significant added value (P = 0.32) as compared to the ER by treatment interaction. Adjuvant chemotherapy was associated with an adjusted hazard ratio for relapse or death of 0.42 [95% confidence interval (CI): 0.17–1.05], 0.54 (95% CI: 0.27–1.08), 0.35 (95% CI: 0.18–0.68), 1.07 (95% CI: 0.81–1.41) for patients with Her2+/ER–, basal-like, Her2–/ER–/nonbasal and luminal-like tumors, respectively.

Conclusion: The breast cancer molecular subclassification was predictive for chemotherapy efficacy in adjuvant setting, but did not provide significant additional information to ER.

Key words: adjuvant chemotherapy, basal like, breast cancer, estrogen receptor, molecular subclassification

{dagger} These authors contributed equally to this work.

Received for publication April 24, 2007. Accepted for publication April 25, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

In this issue

Ann Oncol 2007 18: 1427. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Ann OncolHome page
F.-C. Bidard, M.-C. Matthieu, P. Chollet, I. Raoefils, C. Abrial, J. Domont, M. Spielmann, S. Delaloge, F. Andre, and F. Penault-Llorca
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
Ann. Onc., July 1, 2008; 19(7): 1261 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Sihto, J. Lundin, T. Lehtimaki, M. Sarlomo-Rikala, R. Butzow, K. Holli, L. Sailas, V. Kataja, M. Lundin, T. Turpeenniemi-Hujanen, et al.
Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening
Clin. Cancer Res., July 1, 2008; 14(13): 4103 - 4110.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Andre, K. Broglio, H. Roche, M. Martin, J. R. Mackey, F. Penault-Llorca, G. N. Hortobagyi, and L. Pusztai
Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis
J. Clin. Oncol., June 1, 2008; 26(16): 2636 - 2643.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C.U. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. K. Chia, C. M. Perou, and T. O. Nielsen
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
Clin. Cancer Res., March 1, 2008; 14(5): 1368 - 1376.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.